T Cells In Tumor Immunotherapy Articles & Analysis
11 articles found
What is CD19 Understanding CD19: Definition and Role in the Immune System CD19, also known as Cluster of Differentiation 19, is a cell surface protein belonging to the immunoglobulin superfamily. It serves as a crucial marker for B cells, playing a pivotal role in the human immune system. While predominantly found on the surface of B cells, CD19 is rarely expressed on other immune cells. Its ...
CAR T Cell Therapy CAR T cell therapy is another immunotherapy utilizing cytotoxic T cells. ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. ...
TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, high-affinity clones of antigen-specific T cells. ...
Type 1 diabetes (T1D) is a complex T-cell-mediated autoimmune disease that results in the destruction of insulin-producing beta cells and inadequate insulin secretion. Prior to the discovery of insulin in 1921, patients with T1D died within a year or two of diagnosis. Since the discovery and mass production of insulin, T1D is no longer a terminal disease. However, over time, many patients still ...
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. ...
Using the power of large data and advanced computational methods, researchers can identify peptides on the surface of tumor cells and can target "peptide-centric" chimeric antigen receptors (PC-CARs): a new design of T cells that stimulates the immune response to eliminate tumors. ...
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic ...
Ryan Pawell is the founder and CEO of Indee Labs, a Berkeley biotech. The mission of Indee Labs is to use microfluidic vortex shedding as a scalable method to deliver CRISPR reagents into cells for developing affordable cell and gene therapies in the future. In our previous blog post, we summarized the work from their latest publication on CRISPR-editing in T cells using microfluidic devices. In ...
The body's immune system is an effective weapon against disease, and immunotherapy of cancer cell research is the current frontier in the treatment of cancer and other diseases. Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure ...